FARAPULSE Pulsed Field Ablation System
Farapulse, Inc. · Decision date Aug 14, 2025
What did the FDA approve?
FDA records P230030/S014 as a supplement to PMA P230030, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 14, 2025.
FDA approval order statement
for a manufacturing site located at Boston Scientific de Costa Rica, S.R.L., El Coyol Alajuela, Coyol, Costa Rica (FEI: 3007695959) to perform ethylene oxide sterilization activities
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 14, 2025
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230030/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Aug 14, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230030. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230030 · Original PMA
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S014 received
Application receipt date recorded by FDA.
P230030/S015 · Related supplement
FARAPULSE Pulsed Field Ablation System
P230030/S014 · FDA decision
Normal 180 Day Track No User Fee
P230030/S013 · Related supplement
FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul
P230030/S012 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARAWAVE NAV Pulsed Field Ablation C
P230030/S017 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAPULSE)
P230030/S019 · Related supplement
FARAPULSE Pulsed Field Ablation System
P230030/S021 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S023 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S022 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAPULSE)
P230030/S018 · Related supplement
FARAPULSE Pulsed Field Ablation System
P230030/S016 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S024 · Related supplement
FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul
P230030/S025 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
Timeline entries are records held by MedtechLedger for P230030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Farapulse, Inc. | PMA approval | Jan 30, 2024 | FDA | |
FARAPULSE Pulsed Field Ablation SystemP230030/S015 | Farapulse, Inc. | PMA supplement | Aug 12, 2025 | FDA |
| Farapulse, Inc. | PMA supplement | Sep 24, 2025 | FDA | |
| Farapulse, Inc. | PMA supplement | Jan 12, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Jan 13, 2026 | FDA | |
FARAPULSE Pulsed Field Ablation SystemP230030/S019 | Farapulse, Inc. | PMA supplement | May 6, 2026 | FDA |
| Farapulse, Inc. | PMA supplement | Jun 5, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Jun 26, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Jul 10, 2026 | FDA | |
FARAPULSE Pulsed Field Ablation SystemP230030/S018 | Farapulse, Inc. | PMA supplement | Aug 6, 2026 | FDA |
| Farapulse, Inc. | PMA supplement | Aug 25, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Sep 4, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Farapulse, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3715 Haven Ave., Suite 110, Menlo Park, CA, 94025
Sources and methodology
- Original FDA record: P230030/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





